Fate Therapeutics (FATE) Misses Q3 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.31), $0.06 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.87 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Benchmark Electronics (BHE) Tops Q2 EPS by 16c; offers guidance
• Kinross Gold (KGC) Reports In-Line Q2 EPS
• Q2 Holdings (QTWO) Tops Q2 EPS by 2c; Offers Guidance